Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lenvatinib Treatment”

287 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 287 results

Testing effectiveness (Phase 2)Study completedNCT04361331
What this trial is testing

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Cholangiocarcinoma, Intrahepatic
Shanghai Zhongshan Hospital 61
Testing effectiveness (Phase 2)Looking for participantsNCT06904014
What this trial is testing

Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

Who this might be right for
HCC
Lei ZHAO 40
Testing effectiveness (Phase 2)Ended earlyNCT05103904
What this trial is testing

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Who this might be right for
Recurrent Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8+5 more
Emory University 3
Large-scale testing (Phase 3)Active Not RecruitingNCT04194775
What this trial is testing

Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
CStone Pharmaceuticals 534
Testing effectiveness (Phase 2)UnknownNCT04834986
What this trial is testing

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Who this might be right for
Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05389527
What this trial is testing

Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma

Who this might be right for
Carcinoma, Hepatocellular
Shanghai Zhongshan Hospital 43
Testing effectiveness (Phase 2)Looking for participantsNCT04803318
What this trial is testing

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultHepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04207086
What this trial is testing

A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

Who this might be right for
Melanoma Stage III
Melanoma Institute Australia 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06409637
What this trial is testing

FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

Who this might be right for
Liver CancerLiver Transplant
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 62
Testing effectiveness (Phase 2)UnknownNCT05509478
What this trial is testing

Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma

Who this might be right for
Biliary Tract Cancer
The First Hospital of Jilin University 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07460206
What this trial is testing

Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment

Who this might be right for
ccRCC
Gruppo Oncologico Italiano di Ricerca Clinica 108
Testing effectiveness (Phase 2)WithdrawnNCT05973903
What this trial is testing

Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma

Who this might be right for
GBM
Tel Aviv Medical Center
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06746961
What this trial is testing

Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
The First Affiliated Hospital of Zhengzhou University 49
Not applicableLooking for participantsNCT06277024
What this trial is testing

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Who this might be right for
Overall Response Rate
Fujian Medical University 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07540832
What this trial is testing

WGI-0301 Plus Lenvatinib in Patients With Advanced HCC

Who this might be right for
Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd. 80
Large-scale testing (Phase 3)Not Yet RecruitingNCT05718232
What this trial is testing

SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)

Who this might be right for
Advanced Hepatocellular Carcinoma
Sun Yat-sen University 136
Testing effectiveness (Phase 2)UnknownNCT06030934
What this trial is testing

Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Fudan University 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04736706
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,854
Not applicableStudy completedNCT06916546
What this trial is testing

SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University 238
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06648525
What this trial is testing

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)
Harbin Medical University 68
Next Page